Welcome to our dedicated page for Edap Tms news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on Edap Tms stock.
EDAP TMS SA (NASDAQ: EDAP) delivers innovative therapeutic ultrasound solutions for urological care through its HIFU and lithotripsy technologies. This news hub provides investors and medical professionals with essential updates on the company's advancements in robotic medical devices, regulatory milestones, and global market strategies.
Access real-time announcements including clinical trial results, product approvals, financial disclosures, and strategic partnerships. Our curated collection features press releases about EDAP's three operational divisions: HIFU tumor ablation systems, ESWL stone treatment devices, and distribution of complementary medical technologies.
Stay informed about developments in minimally-invasive treatment solutions that demonstrate EDAP's commitment to advancing urological care. The resource is regularly updated with material events affecting the company's position in the competitive medical devices sector.
Bookmark this page for streamlined access to verified information about EDAP's technological innovations, international expansion efforts, and research collaborations with leading medical institutions.
EDAP reported robust growth in Q1 2024 with a significant 92% increase in U.S. Focal One® HIFU procedures year-over-year. HIFU revenue rose 10.2% to EUR 5.8 million ($6.3 million), contributing to a total revenue of EUR 14.9 million ($16.1 million), up 0.8% from Q1 2023. Gross profit increased to EUR 6.4 million ($6.9 million), driven by higher treatment revenues. Operating expenses dropped to EUR 11.2 million ($12.1 million) due to a non-recurring compensation expense in Q1 2023. Despite an operating loss of EUR 4.8 million ($5.2 million), net loss improved to EUR 4.5 million ($4.9 million) from EUR 7.5 million ($8.1 million) in Q1 2023. Additionally, EDAP's Phase 3 study on endometriosis is expected to yield results in the latter half of 2024.
EDAP TMS SA announced positive final results from the HIFI Study comparing Focal One® HIFU versus radical prostatectomy at the 119th AUA Annual Meeting. The study showed a higher salvage treatment free survival rate in the HIFU arm, better urinary continence and erectile function outcomes, and demonstrated the effectiveness and safety of robotic HIFU in managing localized prostate cancer. The study enrolled a total of 3,328 patients across 46 centers, highlighting the growing relevance of robotic HIFU in prostate cancer management.
EDAP TMS SA, a global leader in robotic energy-based therapies, will announce its first quarter 2024 financial results on May 16, 2024. The company will host a conference call and webcast with key executives to discuss the results. Investors can join the call to learn more about the financial performance and strategic direction of EDAP.
FAQ
What is the current stock price of Edap Tms (EDAP)?
What is the market cap of Edap Tms (EDAP)?
